- Report
- October 2025
- 160 Pages
Global
From €2962EUR$3,358USD£2,602GBP
€3484EUR$3,950USD£3,061GBP
- Report
- March 2025
- 1400 Pages
Global
From €4322EUR$4,900USD£3,797GBP
- Report
- February 2025
- 148 Pages
Global
From €3636EUR$4,123USD£3,195GBP
€4278EUR$4,850USD£3,758GBP
- Report
- August 2025
- 200 Pages
United States
From €2196EUR$2,490USD£1,930GBP
- Report
- March 2025
- 260 Pages
Middle East
From €2558EUR$2,900USD£2,247GBP
- Report
- March 2025
- 260 Pages
Africa
From €2558EUR$2,900USD£2,247GBP
- Report
- March 2025
- 210 Pages
Latin America
From €2558EUR$2,900USD£2,247GBP
- Report
- March 2025
- 840 Pages
Asia Pacific
From €2558EUR$2,900USD£2,247GBP
- Report
- March 2025
- 980 Pages
Europe
From €2558EUR$2,900USD£2,247GBP
- Report
- June 2025
- 81 Pages
Africa, Middle East
From €3043EUR$3,450USD£2,673GBP
- Report
- February 2025
- 236 Pages
United States
From €7052EUR$7,995USD£6,195GBP
- Report
- December 2024
- 100 Pages
Global
From €5248EUR$5,950USD£4,611GBP
- Report
- August 2024
- 120 Pages
Russia
From €5248EUR$5,950USD£4,611GBP
- Report
- July 2023
- 220 Pages
Global
From €1755EUR$1,990USD£1,542GBP
- Report
- April 2021
China
From €2293EUR$2,600USD£2,015GBP
- Drug Pipelines
- July 2024
- 150 Pages
Global
From €2646EUR$3,000USD£2,325GBP
€3308EUR$3,750USD£2,906GBP
- Report
- November 2023
- 30 Pages
Global
From €1941EUR$2,200USD£1,705GBP
€2426EUR$2,750USD£2,131GBP
- Report
- August 2024
- 150 Pages
Global
From €2646EUR$3,000USD£2,325GBP
€3308EUR$3,750USD£2,906GBP
- Report
- November 2023
- 30 Pages
Global
From €1941EUR$2,200USD£1,705GBP
€2426EUR$2,750USD£2,131GBP
- Report
- February 2024
- 150 Pages
Global
From €4190EUR$4,750USD£3,681GBP

The Human Insulin market is a segment of the Endocrine and Metabolic Disorders Drugs market. It is composed of drugs used to treat diabetes, a condition in which the body does not produce enough insulin or is unable to use the insulin it produces. Human Insulin is a synthetic form of insulin, which is produced in a laboratory and is identical to the insulin produced by the human body. It is used to treat both type 1 and type 2 diabetes. Human Insulin is available in a variety of forms, including short-acting, intermediate-acting, and long-acting. It is typically administered via injection or an insulin pump.
Some companies in the Human Insulin market include Novo Nordisk, Sanofi, Eli Lilly, and Biocon. Show Less Read more